• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Propeller Health touts link between air pollution, rescue inhaler use in nationwide asthma study

November 27, 2018 By Fink Densford

Propeller Health

Propeller Health today touted results from a nationwide study that indicated a direct association between daily air pollution and rescue inhaler use.

Results from the study, which spanned five years and involved more than 2,800 individuals with asthma, were published in the Proceedings of the National Academy of Sciences, the Madison, Wisc.-based company said.

Researchers in the study used nationwide data from Propeller’s digital medicine database to analyze the level of fine particulate mater at the time and location of a person’s rescue inhaler use, the company said.

Results from the study indicated that rescue inhaler use increased significantly with increases in daily fine particulate matter exposure, and that pollution increases had the greatest impact on rescue inhaler use during the summer. Lower-income neighborhoods experienced higher pollution exposure and higher rescue medication use on average as compared to higher-income neighborhoods, according to the study.

Study investigators also indicated that a 12% reduction in fine particulate matter concentration, which is less than the 18% reduction attained between 2010 and 2017, would generate $350 million in economic benefits as well.

“This research is groundbreaking in its ability to explore the impact of air pollution down to the time, date and location that the person experienced asthma symptoms, particularly for symptoms that don’t necessarily result in hospitalization. With data generated from digital medicines, we can analyze exacerbations of chronic disease that were previously unobserved to anyone but the patient or their provider,” lead study author Austin Williams said in a press release.

In June, Propellor Health said that it landed an undisclosed investment from McKesson Ventures, following a $20 million funding round the company announced a month earlier.

Filed Under: Clinical Trials, Featured, Patient Monitoring, Respiratory Tagged With: Propeller Health

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS